Most Recent
AstraZeneca has attacked generic drugmaker Pharmacor’s challenge to a patent extension for its diabetes drug Forxiga, telling a judge that it hinges on the false notion that the protected IP is limited to a single molecule.
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
Arrotex has hit back at a lawsuit by the maker of Maltofer iron supplements, filing a cross-claim alleging its rival’s advertising was false because it conveyed its product was superior to Ferro-grad C.
The maker of Maltofer iron supplements is suing Arrotex over ads that claim its Ferro-grad C iron supplement is faster acting and reduces the risk of constipation.
"Quite unsatisfactory", is how a judge has described a revived intellectual property dispute between German drug maker Merck KGaA and US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
Melbourne-based biopharma Telix has filed a lawsuit against Purdue Research Foundation seeking to invalidate its patent for blockbuster prostate cancer treatment Pluvicto.